No Data
No Data
Zevra Therapeutics to Participate at Upcoming Investor Conferences
JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17
Zevra Therapeutics Announces Availability of MIPLYFFA, First FDA-Approved Treatment for Niemann-Pick Disease Type C, Through AmplifyAssist Patient Support Program
Express News | Zevra Therapeutics Announces U.S. Commercial Availability of Miplyffa™ (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (Arimoclomol) for Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics Gains Momentum With Miplyffa Approval and Market Expansion Potential in Rare Disease Treatment
No Data
No Data
